Provided by Tiger Fintech (Singapore) Pte. Ltd.

ASCLETIS-B

7.250
+0.3505.07%
Volume:4.43M
Turnover:31.52M
Market Cap:6.97B
PE:-50.31
High:7.330
Open:7.000
Low:6.790
Close:6.900
Loading ...

Ascletis Pharma Gets Favorable Phase I Clinical Trial Results for Cholesterol Drug

MT Newswires Live
·
08 Nov 2024

BRIEF-Ascletis Announces Promising Phase I Results In Australia For ASC47, Muscle-Preserving Weight Loss Drug for Obesity

Reuters
·
07 Nov 2024

Ascletis Pharma Inc - Asc47 Shows Muscle-Preserving Weight Loss in Pre-Clinical Studies

THOMSON REUTERS
·
07 Nov 2024

Ascletis Announces Promising Results From a Phase I Study in Australia for First-in-Class Muscle-Preserving Weight Loss Drug Candidate Asc47 for the Treatment of Obesity

THOMSON REUTERS
·
07 Nov 2024

Is Ascletis Pharma (HKG:1672) In A Good Position To Deliver On Growth Plans?

Simply Wall St.
·
08 Oct 2024

US Trade Commission Judge Recommends Importation Ban on Ascletis Pharma's Two Liver Drug Candidates

MT Newswires Live
·
07 Oct 2024

BRIEF-Ascletis Pharma Says Got Initial Determination From US International Trade Commission

Reuters
·
07 Oct 2024

Ascletis Pharma Inc - Initial Determination Found Violation in Importation of Co's Drug Candidates Asc41 & Asc43f Into US

THOMSON REUTERS
·
07 Oct 2024

Ascletis Pharma Inc - on Oct 4, Got Initial Determination From US International Trade Commission, Washington D.c.

THOMSON REUTERS
·
07 Oct 2024

BRIEF-Ascletis Pharma Says Unit's Partner Received U.S. FDA Breakthrough Therapy Designation

Reuters
·
03 Oct 2024

Ascletis Pharma - Unit's Partner Sagimet Biosciences Received U.S. FDA Breakthrough Therapy Designation for Asc40

THOMSON REUTERS
·
03 Oct 2024

Ascletis Pharma Reallocates Proceedings from Global Offering

MT Newswires Live
·
24 Sep 2024

Ascletis Pharma Completes Initial Dosing in Phase 1 Trials of Obesity Drug in the US

MT Newswires Live
·
17 Sep 2024

Ascletis Pharma Inc - Enters Obesity Drug Space With Asc30 Clinical Trials

THOMSON REUTERS
·
17 Sep 2024